PSMA and TSPO Compounds Diagnose Peripheral Nervous System Injuries
Summary
USPTO published patent application US20260108637A1 on April 23, 2026, covering methods for diagnosing peripheral nervous system (PNS) neuropathy by administering TSPO-targeting or PSMA-targeting compounds to a subject and taking an image. The application (filed December 2, 2025, Application No. 19405641) names Martin Gilbert Pomper, Catherine Foss, Sami Tuffaha, and William Michael Padoveno as inventors. CPC classifications indicate pharmaceutical composition applications under A61K.
“Methods for diagnosing a peripheral nervous system (PNS) neuropathy comprising administering to a subject in need of treatment thereof, at least one of a translocator protein (TSPO)-targeting compound or a PSMA-targeting compound and taking an image, are disclosed.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published patent application US20260108637A1 for methods of diagnosing peripheral nervous system (PNS) neuropathy using translocator protein (TSPO)-targeting or prostate-specific membrane antigen (PSMA)-targeting compounds administered to a subject followed by imaging. The application was filed December 2, 2025, and names four inventors. Patent applications establish no compliance obligations and create no binding regulatory requirements — they represent published applications seeking intellectual property protection.
For pharmaceutical and medical device companies developing diagnostic imaging agents targeting TSPO or PSMA for neurological applications, this published application provides visibility into competitors' intellectual property claims in the PNS diagnostic space. Entities should review their own R&D pipelines for potential overlap with the claimed methods.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
USES OF PSMA-TARGETING AND TSPO-TARGETING COMPOUNDS FOR EVALUATION OF INJURIES IN THE PERIPHERAL NERVOUS SYSTEM
Application US20260108637A1 Kind: A1 Apr 23, 2026
Inventors
Martin Gilbert Pomper, Catherine Foss, Sami Tuffaha, William Michael Padoveno
Abstract
Methods for diagnosing a peripheral nervous system (PNS) neuropathy comprising administering to a subject in need of treatment thereof, at least one of a translocator protein (TSPO)-targeting compound or a PSMA-targeting compound and taking an image, are disclosed.
CPC Classifications
A61K 51/0459 A61K 49/0034 A61K 49/0052 A61K 51/0455 A61K 51/0497 A61K 2123/00
Filing Date
2025-12-02
Application No.
19405641
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.